Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.3 million.

  • Seres Therapeutics' Non-cash Items rose 83387.76% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 83387.76%. This contributed to the annual value of $15.3 million for FY2024, which is N/A changed from last year.
  • Per Seres Therapeutics' latest filing, its Non-cash Items stood at $2.3 million for Q3 2025, which was up 83387.76% from $499042.0 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Non-cash Items ranged from a high of $143.2 million in Q2 2021 and a low of $245000.0 during Q3 2024
  • For the 5-year period, Seres Therapeutics' Non-cash Items averaged around $22.0 million, with its median value being $8.9 million (2023).
  • In the last 5 years, Seres Therapeutics' Non-cash Items skyrocketed by 291109.74% in 2021 and then tumbled by 9755.0% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Non-cash Items stood at $28.0 million in 2021, then plummeted by 58.55% to $11.6 million in 2022, then decreased by 13.85% to $10.0 million in 2023, then surged by 53.35% to $15.3 million in 2024, then plummeted by 85.08% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $499042.0 for Q2 2025, and $495252.0 during Q1 2025.